Meningitis Outbreak in the UK: What You Need to Know

A recent cluster of meningococcal infections, including several cases linked to exposure at a nightclub in Kent, has prompted health officials in the United Kingdom to issue warnings and coordinate vaccination programs. This outbreak has renewed focus on meningitis, a serious bacterial infection that can have devastating consequences. Here’s a breakdown of the current situation, who is at risk, and how to protect yourself.

What is Meningococcal Group B Disease?

Meningococcal group B disease is a severe bacterial infection caused by Neisseria meningitidis. It can lead to meningitis, an inflammation of the membranes surrounding the brain and spinal cord, or septicemia, a bloodstream infection. Both conditions are medical emergencies, with symptoms developing rapidly. Even with treatment, invasive meningococcal disease can be fatal in 8% to 15% of cases, and survivors may experience long-term complications such as hearing loss, neurological damage, or limb loss. CNN

Current Outbreak in the UK

As of March 20, 2026, UK health officials have reported 15 laboratory-confirmed cases and 12 suspected cases of meningococcal disease, totaling 27, with two fatalities. CNN Many of the cases have been linked to exposure at Club Chemistry in Canterbury between March 5th and March 15th, when the venue voluntarily closed. UKHSA

Who is Eligible for the MenB Vaccine?

The UK Health Security Agency (UKHSA) is coordinating a targeted vaccination program against Meningitis B (MenB). Currently, the vaccine is being offered to:

• Close contacts of confirmed or suspected cases of meningococcal disease.
• Students at the University of Kent who are normally resident on the Canterbury Campus, including those who have traveled home.
• Some staff living or working in these Halls of Residence who have been offered preventative antibiotics.
• Students who attend other universities in Canterbury, living in halls of residence or off-campus locations where there has been a case, and have been advised to take an antibiotic by UKHSA.
• Sixth form students (years 12 and 13) attending a secondary school or sixth form college in Kent where there has been a confirmed or probable case of meningococcal disease, informed by local risk assessment.
• Anyone who visited or was working at Club Chemistry in Canterbury between March 5th and March 15th.

The program may be expanded as UKHSA continues to assess the ongoing risk. UKHSA Eligible students will receive information from their school or university with details on how to access the vaccine.

Meningitis Vaccinations Available in the UK

Several vaccinations offer protection against meningitis, and the NHS vaccination schedule includes most of these for children. NHS These include:

• MenB vaccine: Protects against meningococcal group B bacteria, a common cause of meningitis in young children. Recommended for babies at 8 weeks, 12 weeks, and with a booster at 1 year. NHS
• 6-in-1 vaccine: Protects against diphtheria, tetanus, whooping cough, hepatitis B, polio, and Haemophilus influenzae type b (Hib). Hib can cause meningitis. Given at 8 weeks, 12 weeks, 16 weeks, and 18 months. NHS
• Pneumococcal vaccine: Protects against serious infections caused by pneumococcal bacteria, including meningitis. Offered to babies at 16 weeks with a booster at 1 year, and a single dose to adults aged 65 or over. NHS
• MMRV vaccine: Protects against measles, mumps, rubella, and chickenpox. Meningitis can sometimes occur as a complication of these infections. Usually given in two doses at 12 months and 18 months. NHS
• MenACWY vaccine: Protects against four types of bacteria that can cause meningitis: meningococcal groups A, C, W, and Y. Offered to teenagers aged 14 and to those up to age 25 who haven’t previously received a MenC vaccine. NHS

Long-Term Impact of Vaccination

The MenB vaccine, routinely used in the infant vaccination program in the UK since 2015, has led to a 75% reduction in MenB disease in vaccinated individuals. UKHSA

Key Takeaways

• A meningitis outbreak is occurring in the UK, particularly in Kent, with two confirmed deaths.
• The outbreak is linked to meningococcal group B disease, a serious bacterial infection.
• Targeted vaccination programs are underway for those at increased risk, including students and contacts of confirmed cases.
• Several vaccines are available to protect against different types of meningitis.